A more efficient way to analyze whole-genome sequencing data has been required due to the increasing need for accurate medical diagnoses. A team of experts at Geneyx analyzes genetic data from hospitals and other health care facilities to provide a more comprehensive, accurate diagnosis. The company uses AI-based bioinformatics for accurate diagnostics within minutes. The platform also provides researchers with better leverage over their entire genome sequencing data, allowing them to identify and research new diseases before they even start.
The increasing use of next-generation sequencing technology for diagnostic purposes is creating a growing volume of genomic data. Biopharmaceutical companies are restricted from combining genomic data with clinical evidence because it is often kept in silos in hospital electronic medical records. But this data isn't available anywhere and can't be analyzed by individual laboratories. Geneyx's proprietary technology allows healthcare companies to combine genomic data with clinical evidence in order to create personalized medicines.
Founded in Israel, Geneyx is a biomedical genomics company. It raised $6.5 million through a seed round that was led by Accenture Ventures, Capri Ventures, and Capri Ventures. The firm is headquartered in Herzliya, Israel, and has offices in Foster City, California. It has also become a member of Accenture Ventures' Project Spotlight, which connects promising software startups to major publicly traded companies. Its mission is to improve clinical diagnosis and create personalized therapies.
Among the company's accomplishments is its integration of Toldot Genetics, a biomedical informatics company. It was previously owned jointly by BATM Advanced Communications, and several minority shareholders. The acquisition will allow Geneyx to incorporate Toldot's TGex next-generation sequencing analysis technology. This will increase its artificial intelligence-based processing capabilities and support the creation of a GeneCards knowledgebase.
While next-generation sequencing is becoming a common diagnostic tool, its limitations include limited access to reference data. For example, most genomic studies are performed using samples from one patient. This means that the results can be filtered out of a large cohort of patients, reducing the risk of misdiagnosis and cancer. Furthermore, it offers biomedical interpretation capabilities. Geneyx is therefore in a better position than others to offer biopharmaceuticals to the general public.
Next-generation sequencing is becoming a popular diagnostic tool for patients with cancer. However, there are some limitations. The reference data are siloed and limited. Moreover, biopharmaceutical companies cannot combine genomic information with real-time clinical evidence because the data are stored in hospital electronic medical records. It is therefore difficult to find a cure. Geneyx's innovative approach in genomics has opened new doors for the company.
Next-generation sequencing is a popular tool for diagnosing cancer. This technology has its limitations. First of all, it cannot provide real-time clinical evidence. It has no clinical significance. It only provides reference data. This technology allows hospitals to link genomic information with real time clinical data, improving the accuracy of diagnosis. Thus, the results of genomic analyses are often inaccurate. As a result, it is difficult to understand disease mechanisms.
While next-generation sequencing is becoming a common diagnostic tool, the silosis of genetic data is inhibiting the development of more effective therapies. Capri Ventures has already provided seed funding of $10 million to the company. Accenture's Project Spotlight accelerator program connects emerging technology startups with global 2000 companies. It plans to use the 55 million patient electronic medical records it has to speed up targeted treatment development with this funding.
The next-generation sequencing technology can now be used in many clinical trials. This technology allows clinicians to create customized treatments for patients based upon genetic testing results. As a result, the technology can be used for research purposes to determine the causes of genetic disorders. In addition, the company's technology can also be utilized in diagnostics to help improve the quality of care. The AI-based platform from the company can provide valuable insights to both patients and physicians.
Another major investment in Geneyx is from Accenture. Accenture is a pioneer in genomics, AI-based AI technology and other areas. This funding helps it deliver accurate results and improves clinical decision-making. It can also be used to improve risk prediction, and prognostication. By using this technology, healthcare providers can quickly make the best possible decisions for their patients. Although the startup is still in its infancy, it has made significant progress in the field of medicine.
geneyx.com :for more information